​

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRVS Stock Forecast

Corvus Pharmaceuticals (CRVS) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $29.80, with a high of $42.00 and a low of $20.00. This represents a 29.51% increase from the last price of $23.01.

- $9 $18 $27 $36 $45 High: $42 Avg: $29.8 Low: $20 Last Closed Price: $23.01

CRVS Stock Rating

Corvus Pharmaceuticals stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

CRVS Price Target Upside V Benchmarks

TypeNameUpside
StockCorvus Pharmaceuticals29.51%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts568
Avg Price Target$29.80$27.00$23.63
Last Closing Price$23.01$23.01$23.01
Upside/Downside29.51%17.34%2.69%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2616---7
Dec, 2516---7
Nov, 2515---6
Oct, 25-5---5
Sep, 25-5---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 22, 2026Roger SongJefferies$42.00$25.8062.79%82.53%
Jan 21, 2026Oppenheimer$32.00$22.5441.97%39.07%
Jan 20, 2026Barclays$28.00$21.4130.78%21.69%
Jan 20, 2026Mizuho Securities$20.00$19.522.46%-13.08%
Jan 20, 2026Sean LeeH.C. Wainwright$27.00$18.2248.19%17.34%
Oct 29, 2025Mizuho Securities$13.00$7.5572.19%-43.50%
Oct 13, 2025Barclays$16.00$6.93130.88%-30.47%
May 20, 2025Graig SuvannavejhMizuho Securities$11.00$3.68198.91%-52.19%
Nov 13, 2024Roger SongJefferies$13.00$3.97227.46%-43.50%
Oct 22, 2024Graig SuvannavejhMizuho Securities$12.00$7.5658.73%-47.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 22, 2026JefferiesBuyBuyhold
Jan 21, 2026OppenheimerOutperformOutperformhold
Jan 20, 2026BarclaysOverweightOverweighthold
Jan 20, 2026H.C. WainwrightBuyBuyhold
Dec 11, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 13, 2025BarclaysOverweightinitialise
Mar 26, 2025OppenheimerOutperformOutperformhold
Jan 02, 2025H.C. WainwrightBuyinitialise
Nov 13, 2024JefferiesBuyBuyhold
May 07, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.56$-1.02----
Avg Forecast$-0.55$-0.92$-0.47$-0.60$-0.50$-0.07
High Forecast$-0.54$-0.90$-0.42$-0.41$-0.28$-0.07
Low Forecast$-0.56$-0.95$-0.53$-0.80$-0.78$-0.07
Surprise %1.82%10.87%----

Revenue Forecast

$0 $15M $30M $45M $60M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$775.00K$4.37M$23.23M$70.57M
High Forecast--$775.00K$4.37M$23.23M$70.57M
Low Forecast--$775.00K$4.37M$23.23M$70.57M
Surprise %------

Net Income Forecast

$-65M $-52M $-39M $-26M $-13M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.03M$-62.29M----
Avg Forecast$-26.29M$-44.50M$-22.79M$-29.06M$-25.28M$-3.24M
High Forecast$-25.82M$-43.30M$-20.05M$-19.69M$-13.28M$-3.24M
Low Forecast$-26.76M$-45.71M$-25.52M$-38.42M$-37.27M$-3.24M
Surprise %2.80%39.97%----

CRVS Forecast FAQ

Is Corvus Pharmaceuticals stock a buy?

Corvus Pharmaceuticals stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Corvus Pharmaceuticals is a favorable investment for most analysts.

What is Corvus Pharmaceuticals's price target?

Corvus Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $29.8 over the next 12 months. The price target range spans from $20 at the low end to $42 at the high end, suggesting a potential 29.51% change from the previous closing price of $23.01.

How does Corvus Pharmaceuticals stock forecast compare to its benchmarks?

Corvus Pharmaceuticals's stock forecast shows a 29.51% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Corvus Pharmaceuticals over the past three months?

  • January 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Corvus Pharmaceuticals’s EPS forecast?

Corvus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.47, marking a -53.92% decrease from the reported $-1.02 in 2024. Estimates for the following years are $-0.6 in 2026, $-0.5 in 2027, and $-0.07 in 2028.

What is Corvus Pharmaceuticals’s revenue forecast?

Corvus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $775K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $4.37M, followed by $23.23M for 2027, and $70.57M for 2028.

What is Corvus Pharmaceuticals’s net income forecast?

Corvus Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-22.788M, representing a -63.42% decrease from the reported $-62.293M in 2024. Projections indicate $-29.055M in 2026, $-25.276M in 2027, and $-3.242M in 2028.